相关实验视频

Updated: Jun 21, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

肺癌患者的二线化疗重新挑战:一项摩洛哥实践研究

Hassan Abdelilah Tafenzi^1,2, Farah Choulli^1,2, Ismail Essadi^2,3

¹Medical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, Morocco.

Frontiers in oncology

|June 9, 2025

概括

在非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC) 中白金失败后,挑战性化疗显示出有限的疗效. 在这个患者群体中观察到贫血和中性质衰竭等血液毒性.

科学领域:

在瘤学瘤学.
临床医学临床医学
药理学药理学是指药理学的学科.

背景情况:

复发的非小细胞肺癌 (NSCLC) 在一线化疗失败后经常接受免疫检查点抑制剂.
对于复发的小细胞肺癌 (SCLC) 存在有限的治疗选择.
这项研究调查了重试化疗在二线基化疗后失败的疗效和安全性.

研究的目的:

评估二线化疗在复发性NSCLC和SCLC患者的疗效.
评估这种治疗策略的血液学安全概况.
为了比较摩洛哥人口中不同的二线饮食.

主要方法:

对155名成年患者 (145名NSCLC,10名SCLC) 的回顾性研究,在基双重化疗期间或之后疾病进展.
主要结局:没有第二次进展的生存率 (PFS) 和整体生存率 (OS).
二级终点:整体应答率,疾病控制率 (DCR) 和血液安全性 (3-4级不良事件).

主要成果:

在NSCLC患者中,二线治疗方案之间没有发现统计学上显著的差异;中位数PFS为4.5个月,中位数OS为10个月.
在SCLC患者中,没有观察到PFS (中位数5.1个月) 的显著差异,但OS显示了群体之间的统计学意义 (中位数5.1个月).
3-4级的血液毒性包括贫血 (19.2%),中性质缺血 (12.3%) 和血小板缺血 (9.1%).

结论:

在一线白金化疗失败后,重新使用单剂化疗或埃洛提尼布在摩洛哥人群中表现出有限的活性.
观察到的血液毒性需要在临床实践中仔细监测.

关键词:

摩洛哥队列的摩洛哥队列化学疗法重新挑战肺癌是一种肺癌.现实世界数据 (RWD)第二行第二行.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

相关概念视频

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...